Abstract
Although multiple clinical trials have demonstrated the efficacy of crizotinib in the treatment of anaplastic lymphoma kinase (ALK) / c-ros oncogene 1 (ROS1) fusion advanced non-small-cell lung cancer (NSCLC), the under-represented populations, as well as the complexities and diversity of day-to-day cancer care are still to be complemented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
